Rockefeller Capital Management
FATE icon

Rockefeller Capital Management’s Fate Therapeutics FATE Stock Holding History

Rockefeller Capital Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-4
Closed – – 2593
2022
Q4 		$0 Hold
4
– – ﹤0.01% 3949
2022
Q3 		$0 Sell
4
-34
-89% -$982 ﹤0.01% 4015
2022
Q2 		$0 Sell
38
-74
-66% -$2.04K ﹤0.01% 4183
2022
Q1 		$4K Buy
112
+104
+1,300% +$4.03K ﹤0.01% 3403
2021
Q4 		$0 Buy
+8
New +$453 ﹤0.01% 3827
2021
Q3 		– Sell
-8
Closed – – 3727
2021
Q2 		$0 Buy
+8
New +$645 ﹤0.01% 3482

Other funds holding FATE

State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Rockefeller Capital Management's FATE Position: Q1 2023 in Review

Rockefeller Capital Management sold out of Fate Therapeutics (FATE) in Q1 2023, closing a stake of 4 shares.

Rockefeller Capital Management first reported a position in FATE in Q2 2021 and held it in 6 quarters. The position peaked at $4K in Q1 2022. 181 funds tracked by Wall St. Rank hold FATE as of Q1 2023.

  • Rockefeller Capital Management reported no remaining Fate Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Rockefeller Capital Management sold 4 Fate Therapeutics shares in Q1 2023.
  • Rockefeller Capital Management first reported a position in Fate Therapeutics in Q2 2021 and held it in 6 quarters.
  • Rockefeller Capital Management's Fate Therapeutics position peaked at $4K in Q1 2022.
  • 181 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2023.

Based on Rockefeller Capital Management's 13F filing for Q1 2023, filed 16 May 2023.